HomeCompareSCLN vs QYLD

SCLN vs QYLD: Dividend Comparison 2026

SCLN yields 17.94% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCLN wins by $38.9K in total portfolio value
10 years
SCLN
SCLN
● Live price
17.94%
Share price
$11.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$5,372.32
Full SCLN calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — SCLN vs QYLD

📍 SCLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCLNQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCLN + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCLN pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCLN
Annual income on $10K today (after 15% tax)
$1,524.66/yr
After 10yr DRIP, annual income (after tax)
$4,566.47/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, QYLD beats the other by $243.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCLN + QYLD for your $10,000?

SCLN: 50%QYLD: 50%
100% QYLD50/50100% SCLN
Portfolio after 10yr
$44.8K
Annual income
$5,515.82/yr
Blended yield
12.30%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCLN buys
0
QYLD buys
0
No recent congressional trades found for SCLN or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCLNQYLD
Forward yield17.94%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$64.3K$25.4K
Annual income after 10y$5,372.32$5,659.31
Total dividends collected$34.5K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: SCLN vs QYLD ($10,000, DRIP)

YearSCLN PortfolioSCLN Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$12,494$1,793.72$10,352$1,192.36+$2.1KSCLN
2$15,463$2,094.42$10,830$1,347.57+$4.6KSCLN
3$18,968$2,422.55$11,460$1,539.07+$7.5KSCLN
4$23,073$2,777.26$12,275$1,777.84+$10.8KSCLN
5$27,845$3,157.31$13,323$2,078.95+$14.5KSCLN
6$33,355$3,561.10$14,667$2,463.34+$18.7KSCLN
7$39,677$3,986.73$16,396$2,960.57+$23.3KSCLN
8$46,886$4,432.07$18,631$3,612.97+$28.3KSCLN
9$55,063$4,894.76$21,548$4,482.15+$33.5KSCLN
10$64,290$5,372.32$25,398$5,659.31+$38.9KSCLN

SCLN vs QYLD: Complete Analysis 2026

SCLNStock

SciClone Pharmaceuticals, Inc. is a global biopharmaceutical company. The Company acquires, develops, and commercializes drugs for treating chronic and life-threatening diseases such as cancer, hepatitis B, hepatitis C, cystic fibrosis, and immune system disorders.

Full SCLN Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this SCLN vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCLN vs SCHDSCLN vs JEPISCLN vs OSCLN vs KOSCLN vs MAINSCLN vs XYLDSCLN vs JEPQSCLN vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.